Your browser is no longer supported. Please, upgrade your browser.
SAVA [NASD]
Cassava Sciences, Inc.
Index- P/E- EPS (ttm)-0.37 Insider Own1.90% Shs Outstand39.95M Perf Week-8.01%
Market Cap1.96B Forward P/E- EPS next Y-0.44 Insider Trans0.00% Shs Float37.46M Perf Month-23.97%
Income-12.70M PEG- EPS next Q-0.16 Inst Own27.50% Short Float23.42% Perf Quarter-61.91%
Sales- P/S- EPS this Y8.80% Inst Trans0.14% Short Ratio1.06 Perf Half Y9.33%
Book/sh6.92 P/B6.61 EPS next Y25.40% ROA-7.40% Target Price- Perf Year417.67%
Cash/sh6.48 P/C7.06 EPS next 5Y- ROE-7.50% 52W Range6.70 - 146.16 Perf YTD570.23%
Dividend- P/FCF- EPS past 5Y35.40% ROI- 52W High-68.73% Beta0.71
Dividend %- Quick Ratio60.30 Sales past 5Y- Gross Margin- 52W Low582.24% ATR5.00
Employees11 Current Ratio60.30 Sales Q/Q- Oper. Margin- RSI (14)37.04 Volatility7.14% 9.30%
OptionableYes Debt/Eq0.00 EPS Q/Q-179.80% Profit Margin- Rel Volume0.28 Prev Close46.56
ShortableYes LT Debt/Eq0.00 EarningsAug 03 BMO Payout- Avg Volume8.27M Price45.71
Recom2.00 SMA20-16.96% SMA50-29.03% SMA200-23.01% Volume2,301,774 Change-1.83%
Jul-15-21Downgrade Cantor Fitzgerald Overweight → Neutral $100
Jul-07-21Reiterated Maxim Group Buy $80 → $190
Apr-27-21Initiated B. Riley Securities Buy $78
Feb-16-21Reiterated H.C. Wainwright Buy $20 → $66
Oct-23-20Initiated Cantor Fitzgerald Overweight $24
Sep-23-20Upgrade H.C. Wainwright Neutral → Buy $20
May-18-20Downgrade H.C. Wainwright Buy → Neutral
May-15-20Downgrade Maxim Group Buy → Hold
Jan-10-20Reiterated Maxim Group Buy $3 → $12
Oct-22-21 10:50PM  
10:50PM  
07:30PM  
05:52PM  
04:30PM  
03:15PM  
02:45PM  
11:40AM  
11:30AM  
11:00AM  
10:16AM  
09:15AM  
09:00AM  
07:50AM  
Oct-21-21 10:35PM  
06:48PM  
04:11PM  
02:44PM  
12:30PM  
10:00AM  
09:31AM  
09:15AM  
08:55AM  
08:30AM  
08:19AM  
05:29AM  
Oct-20-21 11:50PM  
09:03PM  
07:34PM  
07:20PM  
06:40PM  
04:15PM  
03:09PM  
03:08PM  
02:10PM  
12:42PM  
12:40PM  
12:15PM  
12:01PM  
09:19AM  
07:45AM  
06:02AM  
05:40AM  
Oct-19-21 11:04PM  
09:15PM  
07:58PM  
06:28PM  
06:10PM  
05:58PM  
04:32PM  
03:46PM  
12:29PM  
11:00AM  
11:00AM  
09:18AM  
07:50AM  
05:25AM  
Oct-18-21 10:50PM  
08:13PM  
07:35PM  
07:15PM  
06:54PM  
06:18PM  
05:50PM  
05:15PM  
04:30PM  
01:44PM  
01:41PM  
01:40PM  
12:15PM  
11:35AM  
11:00AM  
09:45AM  
09:31AM  
08:45AM  
Oct-17-21 07:30PM  
10:20AM  
Oct-16-21 12:45PM  
10:40AM  
08:03AM  
01:00AM  
Oct-15-21 10:50PM  
09:06PM  
08:49PM  
05:30PM  
04:59PM  
03:15PM  
02:50PM  
09:23AM  
08:30AM  
05:45AM  
Oct-14-21 10:30PM  
07:40PM  
06:48PM  
05:15PM  
04:08PM  
01:49PM  
11:15AM  
10:25AM  
10:00AM  
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GUSSIN ROBERT ZDirectorSep 15Option Exercise27.372,80176,6636,710Sep 21 04:01 PM
BARBIER REMIPresident and CEOJul 20Option Exercise20.232,80156,664326,652Jul 20 05:21 PM
BARBIER REMIPresident and CEOMay 27Option Exercise53.5556,0303,000,4061,134,885May 28 04:01 PM
ROBERTSON SANFORDDirectorMar 30Option Exercise40.897,472305,521920,095Mar 31 09:14 PM
FRIEDMANN NADAVChief Medical OfficerMar 17Option Exercise53.5528,0151,500,20392,428Mar 18 04:06 PM
O DONNELL MICHAEL JDirectorMar 16Option Exercise49.004,669228,7819,257Mar 18 03:59 PM